Is ALX Oncology Holdings Inc. (ALXO) a Buy, Sell, or Hold?
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$2 USD
$0.03 (1.52%)
- Volume
- 767.64K
- Average Volume
- 1.4M
- Market Capitalization
- $269.13M
- P/E Ratio
- -1.21
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $2.66
- Year Low
- $0.44
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.21
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jason Lettmann |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALXO |
| CUSIP | 00166B105 |
| CIK | 0001810182 |
| Web | https://www.alxoncology.com |
| Phone | 650 466 7125 |
| Currency | USD |
| Employees | 43 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.21 |
| Quick Ratio | 7.21 |
| Cash Ratio | 1.60 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.44 |
| Price / Cash Flow | -3.44 |
| Price / Book | 0.72 |
Price Target and Rating
| Average Stock Price Forecast | $4.00 |
| High Stock Price Forecast | $4.00 |
| Low Stock Price Forecast | $4.00 |
| Forecast Upside/Downside | -50.00% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.9 |
| Trailing P/E Ratio | -1.21 |
| PEG Ratio | -0.03 |
| P/E Growth | -0.03 |
| Net Income | $-101.7M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -124.06% |
| Return on Assets | -49.83% |
Financials Score
| AltmanZ Score | -0.69 |
| Piotroski Score | 3.00 |
| Working Capital | 125.39M |
| Total Assets | 178.33M |
| Ebit | -87.34M |
| Market Cap | 265.09M |
| Total Liabilities | 26.98M |
Poll Results
About ALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center wit ... h rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
2026-06-30 16:40:00
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 500,000 shares of ALX Oncology's common stock to Michael Listgarten, General Counsel, on June 29, 2026 in connection with the commencement of his employment. Mr. Listgarten's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Listgarten to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
2026-06-30 08:00:00
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph. D. , After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif. , June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointments of Scott Garland as Chairman of the Board of Directors (the "Board") and Michael Listgarten as General Counsel, effective immediately.
2026-06-30 08:00:00
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif.
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
2026-06-01 08:00:00
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York.
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
2026-05-12 10:41:32
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
2026-05-09 04:01:57
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology Q1 Earnings Call Highlights
2026-05-08 16:07:19
ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continued good execution,” including a February financing and the addition of Jeff Knight as chief development and chief operating officer.
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-08 08:00:00
- Data from Phase 1b/2 trial of evorpaceptzanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer - - Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 - - Phase 1 trial evaluating ALX2004 continues to enroll well, on track for safety data in 2H 2026 - - ALX strengthens leadership team with the appointment of Jeff Knight as Chief Development and Operating Officer - - Company to host webcast including presentation of ESMO Breast data by breast cancer expert Sara Hurvitz, M.
Frequently Asked Questions
-
What is the current ALX Oncology Holdings Inc. (ALXO) stock price?
-
ALX Oncology Holdings Inc.(NASDAQ:ALXO) stock price is $2 in the last trading session. During the trading session, ALXO stock reached the peak price of $2.66 while $0.444 was the lowest point it dropped to. The percentage change in ALXO stock occurred in the recent session was 1.52% while the dollar amount for the price change in ALXO stock was $0.03.
-
ALXO's industry and sector of operation?
-
The NASDAQ listed ALXO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALXO?
-
Lin Yeong-Liang | Senior Vice President of Drug Safety & Pharmacovigilance
Michael Listgarten | General Counsel
Jason W. Lettmann | Chief Executive Officer & Director
Harish Shantharam | Chief Financial Officer
Shelly Wong | Senior Vice President of Finance & Chief Accounting Officer -
How many employees does ALXO have?
-
Number of ALXO employees currently stands at 43. ALXO operates from 323 Allerton Avenue, South San Francisco, CA 94080, US.
-
Link for ALXO official website?
-
Official Website of ALXO is: https://www.alxoncology.com
-
How do I contact ALXO?
-
ALXO could be contacted at phone #650 466 7125 and can also be accessed through its website. ALXO operates from 323 Allerton Avenue, South San Francisco, CA 94080, US.
-
How many shares of ALXO are traded daily?
-
The average number of ALXO shares traded daily for last 3 months was 1.4M.
-
What is the market cap of ALXO currently?
-
The market value of ALXO currently stands at $269.13M with its latest stock price at $2